Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)

@inproceedings{Cervantes2012LongTermSE,
  title={Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF)},
  author={Francisco Cervantes and Jean-Jacques Kiladjian and Dietger Niederwieser and Andres Sirulnik and Viktoriya Stalbovskaya and Mari McQuity and Deborah S. Hunter and Richard S. Levy and Francesco Passamonti and Tiziano Barbui and Giovanni Barosi and Heinz Gisslinger and Alessandro Maria Vannucchi and Laurent Knoops and Claire N Harrison},
  year={2012}
}
Abstract 801 Background: Ruxolitinib is a potent JAK1 & 2 inhibitor that has demonstrated superiority over traditional therapies for the treatment of MF. In the two phase 3 COMFORT studies, ruxolitinib demonstrated rapid and durable reductions in splenomegaly and improved MF-related symptoms and quality of life. COMFORT-II is a randomized, open-label study evaluating ruxolitinib versus BAT in patients (pts) with MF. The primary and key secondary endpoints were both met: the proportion of pts… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 34 CITATIONS

Increasing therapeutic efficacy in MPN.

VIEW 1 EXCERPT
CITES BACKGROUND